- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01760980
Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bloemfontein, South Africa, 9301
- Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male subjects, 18 to 55 years of age and postmenopausal female subjects, 18 years to not older than 75 years of age (inclusive at time of screening).
- Body Mass Index (BMI) between 19 and 33 kg/m2 (relates to a body mass within 15% of ideal body mass for height and age).
- Body mass not less than 50 kg.
- Medical history, vital signs, physical examination, standard 12-lead electrocardiogram (ECG) and laboratory investigations must be clinically acceptable or within laboratory reference ranges for the relevant laboratory tests, unless the investigator considers the deviation to be irrelevant for the purpose of the study.
- Non-smoker or mild to moderate smoker (≤ 10 cigarettes daily).
Females, if:
- Serum follicle-stimulating hormone (FSH) ≥ 25.8 mIU/mL AND a serum estradiol level of ≤ 54.7 pg/mL at screening.
- Not of childbearing potential, e.g., has been surgically sterilized, undergone a hysterectomy, amenorrhea for ≥ 12 months and considered post-menopausal.
Note: In postmenopausal women, the value of the serum pregnancy test may be slightly increased, but if not increasing upon repeat, the female will be included in the study.
• Not on thyroid hormone replacement therapy or on stable thyroid hormone replacement therapy for at least 3 months before the first administration of IMP.
Not on statin therapy or on stable statin therapy for at least 3 months before the first administration of IMP.
• Blood pressure measurements are within the acceptable ranges; or, if diagnosed with hypertension, are on stable therapy for at least 3 months before the first administration of IMP.
Note: Treatment with calcium channel blockers is NOT allowed.
- Written consent given for participation in the study. -
Exclusion Criteria:
- Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
- Current alcohol use > 21 units of alcohol per week for males and > 14 units of alcohol per week for females.
- History of regular exposure to substances of abuse (other than alcohol) within the past year.
- Use of any medication, prescribed or over-the-counter or herbal remedies, within 2 weeks prior to the first administration of IMP, except for medication allowed per inclusion criteria (Section 7.3.1) or if the medication will not affect the outcome of the study in the opinion of the investigator.
- Female hormone replacement therapy (or other medicine containing estrogen, including health food products for menopausal symptoms, as these may contain natural estrogens), within 2 weeks prior to the first administration of IMP.
- Participation in another study with an experimental drug, where the last administration of the previous IMP was within 8 weeks before the first administration of IMP in this study.
- Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the first administration of IMP.
- Treatment within the previous 3 months before the first administration of IMP with any drug with a well-defined potential for adversely affecting a major organ or system.
- A major illness during the 3 months before commencement of the screening period.
- History of hypersensitivity or allergy to the IMP or its excipients or any related medication.
- History of bronchial asthma or any other bronchospastic disease within the past 5 years.
- History of epilepsy.
- History of porphyria.
- Relevant history or laboratory or clinical findings indicative of acute or chronic disease, likely to influence study outcome.
- Systolic blood pressure > 150 mmHg or < 95 mmHg, and/or diastolic blood pressure > 95 mmHg or < 50 mmHg in either the supine or standing position at screening.
- Resting pulse of > 100 beats per minute or < 45 beats per minute in either the supine or standing position at screening.
- Positive serology testing for human immunodeficiency virus (HIV), Hepatitis B, Hepatitis C or syphilis.
- Positive urine screen for drugs of abuse.
- Positive pregnancy test.
- Female subjects of premenopausal endocrine status, including pregnant and lactating women.
- Clinically diagnosed peptic ulceration within the past 5 years.
- History of bleeding disorders.
- Vegetarian or any abnormal diet (for whatever reason).
- Any specific investigational product safety concern. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test product (B)
B: Subjects receive Exemestane 25 mg tablets under fasting conditions
|
Exemestane tablets will be administered under fasting conditions on one occasion
Other Names:
|
Active Comparator: Reference product (A)
A: Subjects receive Aromasin 25 mg tablets on two occasions under fasting conditions
|
Aromasin tablets will be administered under fasting conditions on two occasions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUCt, AUCinf and Cmax of Exemestane 25 mg tablets
Time Frame: 0, 0.333, 0.500, 0.750, 1.000, 1.250, 1.500, 1.750, 2.000, 2.500, 3.000, 3.500, 4.000, 6.000, 8.000, 12.000, 24.000, 36.000, 48.000, 72.000 and 96.000 hours post does
|
0, 0.333, 0.500, 0.750, 1.000, 1.250, 1.500, 1.750, 2.000, 2.500, 3.000, 3.500, 4.000, 6.000, 8.000, 12.000, 24.000, 36.000, 48.000, 72.000 and 96.000 hours post does
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PXL209003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Test product (B) Exemestane
-
Coloplast A/SCompletedStoma Site LeakageDenmark
-
Danone ResearchCompleted
-
Coloplast A/SCompletedColostomy Stoma | Ileostomy StomaDenmark
-
Coloplast A/SCompletedColostomy | IleostomyUnited States, United Kingdom, Netherlands, Denmark
-
Coloplast A/SCompleted
-
Boehringer IngelheimCompleted
-
GlaxoSmithKlineCompletedDenture RetentionUnited States
-
Coloplast A/SCompletedCompliance, PatientDenmark
-
Medicis Global Service CorporationCompletedSeborrheic DermatitisUnited States